Publications by authors named "T Amemiya"
Background Functional claim-associated foods contain raw materials that contribute to enhancing health in Japan. However, certain foods with functional claims fail to meet the disintegration test (DT) criteria of the Japanese Pharmacopoeia (JP). Objective This study assessed the quality of tablet-type, functional claim-associated foods containing Salacia-derived salacinol, using DT and weight variation (WV) tests.
View Article and Find Full Text PDFArticle Synopsis
- Subacute cough is a specific type of cough lasting 3-8 weeks and is primarily caused by cough variant asthma, atopic cough, and sinobronchial syndrome, rather than post-infectious cough as previously believed.
- In a study involving 148 patients, 68.3% developed chronic cough, often stemming from multiple underlying conditions such as cough variant asthma combined with atopic cough.
- The findings highlight the need for careful diagnosis and treatment of multiple causes in patients with subacute cough to prevent progression to chronic cough.
In this study, we experimentally demonstrated that the nonlinear optical coefficient of the original Si can be enhanced by incorporating a metamaterial structure into an existing silicon waveguide. The two-photon absorption coefficient enhanced by the metamaterial structure was 424 cm/GW, which is 1.2 × 10 times higher than that of Si.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the quality of deep learning-reconstructed fluid-attenuated inversion recovery (DLR-FLAIR) images from undersampled data and compare them to fully sampled standard FLAIR images.
- Thirty patients with white matter hyperintensities were examined, with fully sampled images taken and accelerated images created using one-third of that data through deep learning.
- Results showed that DLR-FLAIR images had significantly less noise and better quality, as rated by neuroradiologists, and closely matched the visibility of hyperintensities found in standard FLAIR images, with 97% rated as nearly identical.
Retrospective evaluation of medical information for predicting tazobactam/piperacillin-induced liver injury.
Int J Clin Pharmacol Ther
December 2024
Objective: Tazobactam/piperacillin is a first-line treatment option for hospital-acquired pneumonia; however, drug-induced liver injury (DILI) is relatively frequently observed with tazobactam/piperacillin in clinical practice. This study aimed to verify the usefulness of available patient data for predicting DILI prior to tazobactam/piperacillin administration.
Materials And Methods: Tazobactam/piperacillin-treated patients were retrospectively selected and divided into patients with and without DILI.